

Human ILT4/CD85d APC-conjugated Antibody

Monoclonal Mouse IgG_{2A} Clone # 287219

Catalog Number: FAB2078A 100 TESTS, 25 TESTS


| DESCRIPTION | | | |
|--------------------|---|--|--|
| Species Reactivity | Human | | |
| Specificity | Detects human ILT4 in direct ELISAs and Western blots. In direct ELISAs and Western blots, no cross-reactivity with recombinant human (rh) ILT1, rhILT2, rhILT3, rhILT6, rhILT1, rhILT11, rhIR6 or rhIR8 is observed. | | |
| Source | Monoclonal Mouse IgG _{2A} Clone # 287219 | | |
| Purification | Protein A or G purified from hybridoma culture supernatant | | |
| Immunogen | Mouse myeloma cell line NS0-derived recombinant human ILT4 Gly24-His458 Accession # ACT64556 | | |
| Conjugate | Allophycocyanin Excitation Wavelength: 620-650 nm Emission Wavelength: 660-670 nm | | |
| Formulation | Supplied in a saline solution containing BSA and Sodium Azide. See Certificate of Analysis for details. | | |
| | *Contains <0.1% Sodium Azide, which is not hazardous at this concentration according to GHS classifications. Refer to the Safety Data Sheet (SDS) for additional information and handling instructions. | | |

APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

| | Recommended Concentration | Sample |
|----------------|------------------------------|-----------|
| Flow Cytometry | 10 μL/10 ⁶ cells | See Below |

DATA



Detection of ILT4/CD85d in Human Blood Monocytes by Flow Cytometry. Human peripheral blood monocytes were stained with Mouse Anti-Human ILT4/CD85d APC-conjugated Monoclonal Antibody (Catalog # FAB2078A, filled histogram) or isotype control antibody (Catalog # IC003A, open histogram). View our protocol for Staining Membrane-associated Proteins.

PREPARATION AND STORAGE

Shipping The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Protect from light. Do not freeze.

• 12 months from date of receipt, 2 to 8 °C as supplied.





Human ILT4/CD85d APC-conjugated Antibody

Monoclonal Mouse IgG_{2A} Clone # 287219

Catalog Number: FAB2078A 100 TESTS, 25 TESTS

BACKGROUND

The immunoglobulin-like transcript (ILT) comprise a family of activating and inhibitory type immunoreceptors whose genes are located in the same locus that encodes killer cell Ig-like receptors (KIR) (1–3). ILT4, also known as LIR-2 and LILRB2, is a type I transmembrane protein expressed primarily on monocytes and dendritic cells (DC) (4). Human ILT4 is produced as a 598 amino acid (aa) precursor including a 21 aa signal sequence, a 440 aa extracellular domain (ECD), a 21 aa transmembrane segment, and a 116 aa cytoplasmic domain. The ECD contains four Ig-like domains, and the cytoplasmic domain contains three immunoreceptor tyrosine-based inhibitory motifs (ITIM) (5). The ECD of human ILT4 shares 76% aa identity with chimpanzee ILT4 and 74%, 81%, 33%, 52%, 77%, 61%, and 64 % aa identity with human ILT1, 2, 3, 5, 6, 7, and 8, respectively. ILT4 binds to classical MHC I proteins as well as the non-classical HLA-G1 and HLA-F molecules (5–9). It competes with CD8α for MHC I binding but does not compete with KIR2DL1 (7). Ligation of ILT4 induces Tyr phosphorylation within its cytoplasmic ITIMs, a requirement for association with SHP-1 (4, 6). Activation of ILT4 inhibits signaling through Fcy RI (4) and Fcɛ RI (6) and causes DC to become tolerogenic by downregulation of costimulatory molecules (10, 11). ILT4 mediates tolerogenic DC-induced CD4+T cell energy *in vitro* and *in vivo* (10–12).

References:

- 1. Suciu-Foca, N. et al. (2005) Int. Immunopharmacol. 5:7.
- 2. Hofmeister, V. and E.H. Weiss (2003) Semin. Canc. Biol. 13:317.
- 3. Hunt, J.S. et al. (2005) FASEB J. 19:681.
- 4. Finger, N.A. et al. (1998) Eur. J. Immunol. 28:3423.
- Borges, L. et al. (1997) J. Immunol. 159:5192.
- 6. Colonna, M. et al. (1998) J. Immunol. **160**:3096.
- 7. Shiroishi, M. et al. (2003) Proc. Natl. Acad. Sci. 100:8856.
- 8. Lepin, E.J.M. et al. (2000) Eur. J. Immunol. 30:3552.
- 9. Allen, R.L. et al. (2001) J. Immunol. 167:5543.
- 10. Chang, C.C. et al. (2002) Nat. Immunol. 3:237.
- Ristich, V. *et al.* (2005) Eur. J. Immunol. **35**:1133.
 Manavalan, J.S. *et al.* (2003) Transpl. Immunol. **11**:245.

